D e l i v e r   H o p e   f o r   a   B e t t e r   L i f e

Press Release

• Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
  2024/10/02
• Menagen and Pharmosa Announce In-Licensing Collaboration for Sustained-Release Inhaled Treprostinil Product in MENAT Region
  2024/09/02
• Pharmosa announced the collaboration with Liquidia Technologies, Inc. For L606 in North America
  2023/06/28
• L606 Poster presented at 2022 ATS Conference
  2022/05/16
• Enlisted in Emgerging Market, Stock code: 6875
  2022/02/22
• L606 launched phase III pivotal trial in US
  2021/08/25
• Funded by a MOEA Government grant
  2017/10/30
• Notification of Company Name Change and Relocation of Headquarters
  2016/10/30
• MOEA approves Pharmosa Limited as a New Pharmaceuticals Company
  2014/09/30